Matthew Sniegowski, MD
Ophthalmology · Leawood, KSNPI 1033360094
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,550 of the $21,870 with a category attached, or 84.8%. Amgen accounts for 97.6% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2020 at $10,473 and has fallen 98.6% since, to $147 in 2025. Among ophthalmology clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 63 payments — averaging $347.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$21K
- Alcon$168
- Stryker$96
- Sight Sciences, Inc.$61
- ANI Pharmaceuticals, Inc.$60
- Galderma Laboratories, L.p.$45
- plus $103 from 4 others
What the payments were for
- Speaking & faculty fees$18,55085%
- Travel & lodging$1,0655%
- Food & beverage$2,25510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 49 | $21,338 |
| Alcon | 4 | $168 |
| Stryker | 1 | $96 |
| Sight Sciences, Inc. | 1 | $61 |
| ANI Pharmaceuticals, Inc. | 2 | $60 |
| Galderma Laboratories, L.p. | 2 | $45 |
| Bausch & Lomb Americas Inc. | 1 | $34 |
| Globus Medical | 1 | $27 |
| Sanofi | 1 | $26 |
| Novartis | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$19,608
How this compares
$21,870 in reported general payments places this provider in the 90th percentile of 135 ophthalmology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 408 | $3,898 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 124 | $1,357 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 25 | $1,320 |
| Prednisolone Acetate | 28 | $773 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 49 | $317 |
| Methylprednisolone | 19 | $115 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Leawood
- John DoaneLeawood$496K
- Timothy WallineLeawood$5K
- Alaina GerenLeawood$4K
- Kevin PikeyLeawood$3K
- Alexander VuLeawood$2K
- Daniel DurrieOverland Park$974K
- John HunkelerOverland Park$218K
- Christopher PoleOverland Park$129K
- Blake CooperLenexa$100K
- Miranda BisharaPrairie Village$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.